Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib.
SIK2
SRC-kinases
biomarker
dasatinib
gastric cancer
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
04 Feb 2020
04 Feb 2020
Historique:
received:
16
11
2019
accepted:
13
01
2020
entrez:
22
2
2020
pubmed:
23
2
2020
medline:
23
2
2020
Statut:
epublish
Résumé
Gastric cancer (GC) remains the third leading cause of cancer-related death despite several improvements in targeted therapy. There is therefore an urgent need to investigate new treatment strategies, including the identification of novel biomarkers for patient stratification. In this study, we evaluated the effect of FDA-approved kinase inhibitors on GC. Through a combination of cell growth, migration and invasion assays, we identified dasatinib as an efficient inhibitor of GC proliferation. Mass-spectrometry-based selectivity profiling and subsequent knockdown experiments identified members of the SRC family of kinases including
Identifiants
pubmed: 32082487
doi: 10.18632/oncotarget.27462
pii: 27462
pmc: PMC7007292
doi:
Types de publication
Journal Article
Langues
eng
Pagination
535-549Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204724/Z/16/Z
Pays : United Kingdom
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST MF is a founder, shareholder and the CEO of msAId GmbH. The work presented here was not in any way related to this affiliation. The remaining authors declare no conflicts of interest.
Références
Cancer. 2006 Oct 15;107(8):1918-29
pubmed: 16986126
J Clin Oncol. 2016 May 1;34(13):1448-54
pubmed: 26884585
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32
pubmed: 16203784
Front Oncol. 2019 Jan 22;9:18
pubmed: 30723708
Eur J Med Chem. 2017 Dec 15;142:152-162
pubmed: 28780190
Cancer Cell. 2010 Aug 9;18(2):109-21
pubmed: 20708153
Cancer Metastasis Rev. 2016 Jun;35(2):179-99
pubmed: 27067725
Life Sci. 2016 Jul 15;157:52-61
pubmed: 27245276
J Biomed Sci. 2018 Mar 6;25(1):20
pubmed: 29506506
Asia Pac J Clin Oncol. 2019 Aug;15(4):208-217
pubmed: 31111678
Oncotarget. 2016 Jul 12;7(28):43997-44012
pubmed: 27259267
ACS Chem Biol. 2015 Jan 16;10(1):201-12
pubmed: 25474541
Cancer Res. 2005 Oct 15;65(20):9185-9
pubmed: 16230377
Cancer Cell. 2016 Aug 8;30(2):273-289
pubmed: 27478041
Oncol Lett. 2017 Aug;14(2):2103-2110
pubmed: 28781651
J Am Chem Soc. 2012 Feb 15;134(6):3001-14
pubmed: 22242683
Angew Chem Int Ed Engl. 2018 Apr 9;57(16):4372-4385
pubmed: 28994500
Expert Opin Ther Targets. 2016;20(4):477-85
pubmed: 26549013
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
J Leukoc Biol. 2016 May;99(5):711-21
pubmed: 26590148
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Methods Mol Biol. 2016;1470:103-19
pubmed: 27581288
Stem Cells Int. 2018 Feb 28;2018:5416923
pubmed: 29681949
Mol Cancer Res. 2018 Oct;16(10):1590-1600
pubmed: 29866925
Cell Mol Gastroenterol Hepatol. 2017 Feb 20;3(3):331-338
pubmed: 28462375
Cancer Lett. 2016 Mar 28;372(2):187-91
pubmed: 26797419
Mol Cancer. 2018 Feb 19;17(1):48
pubmed: 29455673
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
World J Gastroenterol. 2012 Apr 7;18(13):1531-7
pubmed: 22509086
ChemMedChem. 2018 Aug 20;13(16):1629-1633
pubmed: 29928781
Biomed Res Int. 2013;2013:546318
pubmed: 23986907
Clin Cancer Res. 2017 Mar 15;23(6):1586-1597
pubmed: 27620279
Nat Chem Biol. 2010 Apr;6(4):291-9
pubmed: 20190765
Br J Cancer. 2016 Feb 16;114(4):381-7
pubmed: 26882063
FEBS Open Bio. 2018 Mar 23;8(5):732-742
pubmed: 29744288
Clin Exp Pharmacol Physiol. 2017 Jun;44(6):613-622
pubmed: 28271563
BMC Cancer. 2017 Jan 31;17(1):87
pubmed: 28143619
Tumour Biol. 2016 Sep;37(9):12049-12059
pubmed: 27179963
Mol Carcinog. 2015 Oct;54(10):1181-93
pubmed: 24976598
BMC Cancer. 2016 Aug 31;16:699
pubmed: 27582078
J Exp Clin Cancer Res. 2016 Jan 04;35:1
pubmed: 26728266
Cancer Treat Rev. 2010 Oct;36(6):492-500
pubmed: 20226597
J Proteome Res. 2015 Mar 6;14(3):1574-86
pubmed: 25660469
Crit Rev Oncol Hematol. 2016 Apr;100:141-6
pubmed: 26947813
Nat Biotechnol. 2007 Sep;25(9):1035-44
pubmed: 17721511
PLoS One. 2015 Dec 30;10(12):e0146021
pubmed: 26717316
Clin Ther. 2007 Nov;29(11):2289-308
pubmed: 18158072
World J Gastroenterol. 2016 May 28;22(20):4812-23
pubmed: 27239108
Genes Chromosomes Cancer. 2005 Mar;42(3):269-79
pubmed: 15611931
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Transl Oncol. 2018 Jun;11(3):575-584
pubmed: 29547756
Neoplasia. 2010 Aug;12(8):599-607
pubmed: 20689754
Expert Opin Investig Drugs. 2010 Mar;19(3):415-25
pubmed: 20113198
Br J Cancer. 2018 Apr;118(7):936-937
pubmed: 29545596
J Clin Oncol. 2014 Jul 1;32(19):2039-49
pubmed: 24868024
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet Oncol. 2013 May;14(6):490-9
pubmed: 23594786
World J Gastroenterol. 2016 Jan 21;22(3):1160-71
pubmed: 26811654
Br J Cancer. 2016 Oct 11;115(8):974-982
pubmed: 27623234
Mol Cancer Res. 2015 Apr;13(4):620-635
pubmed: 25548099
Trends Pharmacol Sci. 2015 Jul;36(7):422-39
pubmed: 25975227
Science. 2017 Dec 1;358(6367):
pubmed: 29191878
Sci Rep. 2016 Mar 03;6:22371
pubmed: 26934957
Curr Opin Pharmacol. 2014 Aug;17:58-63
pubmed: 25113945
Oncotarget. 2016 Sep 20;7(38):62049-62069
pubmed: 27557490